Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
Latest news on ULTRAGENYX PHARMACEUTICAL
10/19ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Brazil for the Tre..
AQ
10/18Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazi..
GL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/19ULTRAGENYX PHARMACEUTICAL : appoints Dr. Wladimir Hogenhuis as COO
AQ
09/17ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers, Fina..
AQ
09/17Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chi..
GL
08/30Ultragenyx to Present at Upcoming Investor Conferences
GL
08/30ULTRAGENYX PHARMACEUTICAL : FDA clarifies path to submission for Ultragenyx's ra..
AQ
08/29ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
08/29ULTRAGENYX PHARMACEUTICAL : Announces FDA Accepts Proposal to Submit an NDA for ..
AQ
08/28ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Europe for the Tre..
AQ
08/28ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii (vestronidase alfa) i..
AQ
08/27Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europ..
GL
08/22ULTRAGENYX PHARMACEUTICAL INC. : Temporary Suspension of Trading Under Registran..
AQ
08/03ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
08/03ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure, Financial Statements ..
AQ
08/03ULTRAGENYX : 2Q Earnings Snapshot
AQ
08/02ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
08/02Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
GL
07/31ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Second Quarter 2018 Fina..
AQ
07/31ULTRAGENYX PHARMACEUTICAL : doses first patient in DTX401 Phase 1/2 study to tre..
AQ
07/27ULTRAGENYX PHARMACEUTICAL : Announces First Patient Dosed in Phase 1/2 study of ..
AQ
07/27Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results ..
GL
07/26ULTRAGENYX PHARMACEUTICAL : Announces First Patient Dosed in Phase 1/2 study of ..
AQ
07/04ULTRAGENYX PHARMACEUTICAL : Announces Positive CHMP Opinion for Mepsevii for the..
AQ
06/29Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase ..
GL
06/21ULTRAGENYX PHARMACEUTICAL INC. : Submission of Matters to a Vote of Security Hol..
AQ
06/08ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form..
AQ
06/04ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/23Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
GL
05/22Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results
AQ
05/21Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
AQ
05/18Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
AQ
05/17Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
GL
05/11Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
05/11ULTRAGENYX PHARMACEUTICAL : Reports First Quarter 2018 Financial Results and Cor..
AQ
05/08ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
05/07ULTRAGENYX : 1Q Earnings Snapshot
AQ
05/07ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
05/07Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update
GL
05/04ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for First Quarter 2018 Finan..
AQ
05/03Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
05/01Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results a..
GL
04/30Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched i..
GL
04/23Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug ..
GL
04/17ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
04/17Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza..
GL
03/30ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement, Fin..
AQ
03/23ULTRAGENYX PHARMACEUTICAL INC. : Other Events (form 8-K)
AQ
03/08Ultragenyx to Present at Upcoming Investor Conferences
GL
03/08ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Results and DMC Review fr..
AQ
03/07ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
03/07ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Results and DMC Review fr..
AQ
02/26Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing A..
AQ
02/26XLH therapy burosumab gains EU approval
AQ
02/23ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
02/23Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditiona..
GL
02/21ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
02/21ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
02/20ULTRAGENYX PHARMACEUTICAL : reports 4Q loss
AQ
02/20ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
02/20Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Co..
GL
02/16ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full ..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full ..
PU
02/14Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 Fin..
GL
02/08Ultragenyx to Present at Leerink Partners Global Healthcare Conference
GL
02/01ULTRAGENYX PHARMACEUTICAL : Appoints Camille L. Bedrosian, M.D. as Chief Medical..
AQ
01/29Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and E..
GL
1  2  3  4Next
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,0x
EV / Sales 2019 27,4x
Capitalization 3 176 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 219
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222